Your browser doesn't support javascript.
loading
Capsid virus-like particle display improves recombinant influenza neuraminidase antigen stability and immunogenicity in mice.
Kang, Hyeog; Martinez, Mira Rakic; Aves, Kara-Lee; Okholm, Anna Kathrine; Wan, Hongquan; Chabot, Sylvie; Malik, Tahir; Sander, Adam F; Daniels, Robert.
Afiliação
  • Kang H; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.
  • Martinez MR; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.
  • Aves KL; Department of Immunology and Microbiology, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Okholm AK; Department of Immunology and Microbiology, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Wan H; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.
  • Chabot S; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.
  • Malik T; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.
  • Sander AF; Department of Immunology and Microbiology, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Daniels R; AdaptVac, Ole Maaløes Vej 3, 2200 Copenhagen, Denmark.
iScience ; 27(6): 110038, 2024 Jun 21.
Article em En | MEDLINE | ID: mdl-38883830
ABSTRACT
Supplementing influenza vaccines with additional protective antigens such as neuraminidase (NA) is a promising strategy for increasing the breadth of the immune response. Here, we improved the immunogenicity and stability of secreted recombinant NA (rNA) tetramers by covalently conjugating them onto the surface of AP205 capsid virus-like particles (cVLPs) using a Tag/Catcher ligation system. cVLP display increased the induction of IgG2a subclass anti-NA antibodies, which exhibited cross-reactivity with an antigenically distant homologous NA. It also reduced the single dose rNA amounts needed for protection against viral challenge in mice, demonstrating a dose-sparing effect. Moreover, effective cVLP-display was achieved across different NA subtypes, even when the conjugation was performed shortly before administration. Notably, the rNA-cVLP immunogenicity was retained upon mixing or co-administering with commercial vaccines. These results highlight the potential of this approach for bolstering the protective immune responses elicited by influenza vaccines.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article